LLS COVID-19 Antibody Research Study: Your Questions Answered
Please note, with the fast developing knowledge on this topic, some recommendations may change as new data emerges. Click here to access the latest LLS information and resources on COVID-19.
This program will update you on the results so far regarding LLS’s COVID-19 Antibody Research Study. In February 2021, LLS began to collect data regarding COVID 19 in the LLS patient registry. LLS understood that COVID antibody research needed to be done, and so, in February this study began and over the ensuing months, the Registry has had over 3,500 patients take part in this study. The LLS registry now is over 8,000 patients. The study is ongoing and will be continuing not only to understand the safety and efficacy of the vaccines, but soon some information about whether other parts of the immune system, besides antibodies, are important for a patient’s ability to respond to the vaccine.
Note: This video has been updated to include the Special Booster Update. To watch only the Special Booster Update, watch the second video on this page.
Larry Saltzman, MD
Executive Research Director
The Leukemia & Lymphoma Society
LLS COVID-19 Antibody Study - Special Booster Update
Since the initial recording of this webinar, a 3rd dose of the COVID vaccine was approved for certain immunocompromised individuals. Dr. Saltzman is back to give information about the new FDA authorization and what this means for blood cancer patients.
Note: The full video above has been updated to include the Special Booster Update. The video below was pulled from the full video.
Support for this program provided by BeiGene, Ltd.; Bristol Myers Squibb; Pharmacyclics, An AbbVie Company & Janssen Biotech and Pfizer Inc.